Shalbafan M, Mohammadinejad P, Shariat S-V, Alavi K, Zeinoddini A, Salehi M, Askari N, Akhondzadeh S
School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Pharmacopsychiatry. 2015 Jul;48(4-5):136-40. doi: 10.1055/s-0035-1549929. Epub 2015 May 6.
A growing body of evidence implicates inflammatory cascades in the pathophysiology of obsessive-compulsive disorder (OCD), making this pathway a target for development of novel treatments.
50 outpatients with moderate to severe OCD participated in the trial, and underwent 10 weeks of treatment with either celecoxib (200 mg twice daily) or placebo as an adjuvant to fluvoxamine. Participants were investigated using Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The main outcome measure was to assess the efficacy of celecoxib in improving the OCD symptoms.
General linear model repeated measures demonstrated significant effect for time × treatment interaction on the Y-BOCS total scores [F (1.38, 66.34)=6.91, p=0.005]. Kaplan-Meier estimation with log-rank test demonstrated significantly more rapid response in the celecoxib group than the placebo group (p<0.001). There was no significant difference in adverse event frequencies between the groups.
The results of the current study suggest that celecoxib could be a tolerable and effective adjunctive treatment for more rapid and more satisfying improvements in OCD symptoms.
越来越多的证据表明炎症级联反应在强迫症（OCD）的病理生理学中起作用，这使得该途径成为新型治疗方法开发的靶点。
50名中度至重度强迫症门诊患者参与了该试验，接受了为期10周的塞来昔布（每日两次，每次200毫克）或安慰剂治疗，作为氟伏沙明的辅助治疗。使用耶鲁-布朗强迫症量表（Y-BOCS）对参与者进行调查。主要结局指标是评估塞来昔布改善强迫症症状的疗效。
一般线性模型重复测量显示，时间×治疗交互作用对Y-BOCS总分有显著影响[F（1.38，66.34）=6.91，p=0.005]。采用对数秩检验的Kaplan-Meier估计显示，塞来昔布组的反应明显比安慰剂组更快（p<0.001）。两组之间不良事件发生率无显著差异。
本研究结果表明，塞来昔布可能是一种耐受性良好且有效的辅助治疗方法，可更快、更令人满意地改善强迫症症状。
